10 results about "Translation termination" patented technology

The invention discloses a recombinant three-type collagen raw material and a medical beauty repair anti-aging product, and relates to the technical field of genetic engineering. The similarity between the amino acid sequence of the recombinant III-type collagen provided by the invention and the sequence shown in SEQ ID NO: 1 is greater than 99%, and the recombinant III-type collagen has the following characteristics that the soluble expression proportion is not less than 80% in an escherichia coli, pichia pastoris, bacillus or bacillus subtilis expression system. Through accurate sequence design and optimization, early translation termination and misfolding are effectively reduced, the effect of efficient expression in different expression systems (such as escherichia coli, pichia pastoris, bacillus and bacillus subtilis) is achieved, the soluble expression proportion is higher than 80%, the downstream purification difficulty and production cost are directly reduced, and the method is suitable for industrial production. And a foundation is laid for large-scale industrial production. Experiments prove that the recombinant three-type collagen provided by the invention has a good effect of promoting cell proliferation, and can be applied to preparation of drugs or medical equipment products for promoting cell proliferation or skin repair.

Genomically recoded organisms (GRO) are provided. In some forms, the GRO include no more than 25 genomic instances of the TGA codon. In some forms, genomically recoded organisms include two or more of single nucleotide substitutions, TAA insertions, and deletions to eliminate most or all of the TGA codons relative to a progenitor cell. In some forms, the GRO have a genome having stops codons, wherein the stop codons consisting of a single stop codon sequence. In some forms, the GRO provides translation termination only at the single stop codon sequence. Also provided are (i) a mutant release factor 2 (RF2) with reduced ability to terminate translation at UGA and / or a nucleic acid encoding the same and (ii) a mutant tRNATrp with reduced ability to decode UGA and / or a nucleic acid encoding the same, relative to a progenitor cell. GRO's expressing (i) and / or (ii) are also provided.

A site-specifically-modified engineered tRNA and the use thereof. Said modification refers to replacement, with one or more modified nucleotides, of one or more native unmodified nucleotides selected from sites 4, 9, 13, 14, 17, 18, 27, 28, 32, 34, 35, 36, 37, 38, 39, 49, 50, 54, 55, 58 and 72 of a tRNA molecule. Compared with unmodified tRNAs, the site-specifically-modified tRNA has higher structural stability and / or higher nuclease degradation resistance, the aminoacylation efficiency thereof is not remarkably reduced, and immunogenicity thereof is not remarkably increased. The modified tRNA can be used for eliminating premature translation terminations caused by nonsense mutations, and thus has great application potentials in treating nonsense mutation-related genetic diseases, tumors, etc. The modification of the engineered tRNA also provides valuable insights for drug development of tRNAs and thus can guide the modification design of native tRNAs.

This invention provides a method for preparing sweet and waxy maize with the same kernel size and its application, relating to the field of bio-breeding technology. This invention identifies and obtains for the first time a new sweet and waxy maize germplasm material, TZNB25341, formed by natural mutation. For the aforementioned new material TZNB25341, this invention conducts in-depth analysis of its key controlling genes for sweet and waxy maize with the same kernel size, and carries out systematic gene mapping and cloning studies on the genetic regulatory mechanism of this trait. It was discovered that in TZNB25341… ZmSH1 A 5979 bp retrotransposon LTR was inserted into the exon 13 region of the (Zm00001eb374090) gene. The insertion of this transposon led to three premature translation termination sequences and a significant decrease in transcription level in the exon, resulting in phenotypic changes in TZNB25341, which ultimately manifested as the sweet and sticky phenotype.

The present invention relates to a method for identifying a pharmaceutically active compound that modulates the rpL23-dependent translation of at least one mRNA in a mammalian cell, in particular the mRNA encoding the mutated TP53 protein. The at least one mRNA may include a premature termination codon (PTC) or undergo premature translation termination. Furthermore, a screening system, methods for treating or preventing a disease or condition, such as cancer, and screened compounds or derivatives thereof are provided.

Genomically recoded organisms (GRO) are provided. In some forms, the GRO include no more than 25 genomic instances of the TGA codon. In some forms, genomically recoded organisms include two or more of single nucleotide substitutions, TAA insertions, and deletions to eliminate most or all of the TGA codons relative to a progenitor cell. In some forms, the GRO have a genome having stops codons, wherein the stop codons consisting of a single stop codon sequence. In some forms, the GRO provides translation termination only at the single stop codon sequence. Also provided are (i) a mutant release factor 2 (RF2) with reduced ability to terminate translation at UGA and / or a nucleic acid encoding the same and (ii) a mutant tRNATrp with reduced ability to decode UGA and / or a nucleic acid encoding the same, relative to a progenitor cell. GRO's expressing (i) and / or (ii) are also provided.

The invention discloses an RNA (Ribonucleic Acid) aptamer of a targeted translation termination factor eRF1 and application of the RNA aptamer in improving the drought tolerance of rice. A high-affinity aptamer Dart1 which is specifically combined with rice eRF1 and has a nucleotide sequence as shown in SEQ ID NO.1 is screened from an RNA library containing a 40nt random region, the high-affinity aptamer Dart1 can inhibit the release activity of a terminator of the eRF1 and improve translation termination read-through, the survival rate of a plant can be remarkably increased under a drought condition, and the high-affinity aptamer Dart1 is a high-affinity aptamer Dart1 which is specifically combined with the rice eRF1. The growth is recovered; the chlorophyll content is increased; the electrolyte leakage is reduced; and the drought-resistant related gene expression is enhanced. The aptamer regulation strategy provided by the invention has the advantages of high specificity, reversibility and no need of permanently changing genomes, provides a novel and efficient molecular tool for quickly improving the drought tolerance of crops, and is suitable for breeding and field application of crops such as rice.

The application discloses an RNA aptamer targeting a translation termination factor eRF1 and application thereof to improving drought resistance of rice. The application screens a high-affinity aptamer Dart1 which is specific to eRF1 of rice and has a nucleotide sequence as shown in SEQ ID NO. 1 from an RNA library containing a 40 nt random region, and the aptamer can inhibit the terminator release activity of eRF1 and improve translation termination read-through, can significantly improve the survival rate of plants under drought conditions, and can exhibit growth recovery, increased chlorophyll content, reduced electrolyte leakage and enhanced expression of drought resistance-related genes. The aptamer regulation strategy provided by the application has the advantages of high specificity, reversibility and no need to permanently change the genome, and provides a novel and efficient molecular tool for rapidly improving drought resistance of crops, and is suitable for breeding and field application of crops such as rice.

The invention discloses a fusion protein, an RNA editing level detection method and application thereof, and relates to the technical field of nucleic acid editing.The fusion protein comprises a first protein and a second protein, and the first protein comprises any one of a translation initiation factor and a translation termination factor; the second protein comprises deaminase; the fusion protein is used for editing RNA at the beginning or ending of translation. Wherein the translation initiation factor and the translation termination factor are respectively combined with the RNA chain at the translation initiation and the translation termination, so that the fusion protein is in contact with the RNA, and all the RNA for translation initiation and translation termination are more accurately positioned; when the fusion protein is in contact with the RNA, the deaminase performs deamination editing on nucleotides near the contact point, so that a marker for RNA editing is left, and the RNA translation level can be detected by using the marker.

The invention relates to the technical field of biology, in particular to a nucleic acid molecule, a carrier containing the nucleic acid molecule, a host cell, a pharmaceutical composition and application of the nucleic acid molecule and the carrier. The nucleic acid molecule is particularly suitable for gene therapy and can be applied to the scene of treatment of various diseases.